Observational studyPloS one2021

Real-world outcomes of first- and second-generation tyrosine kinase inhibitors first-line in patients with epidermal growth factor receptor mutation-positive non-small cell lung cancer: A retrospective observational cohort study.

Wei-Wei Ng et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.